Novartis (NVS) broke ground on its new 46,000 sq. ft radioligand therapy manufacturing site in Denton, Texas, the latest milestone in its broader $23B investment in U.S. manufacturing and research. The start of construction on the company’s first Texas-based manufacturing facility brings US RLT production closer to patients across the southern U.S., becoming the fifth RLT site nationwide.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- 3 Best Vanguard Dividend ETFs for Stable Income in 2026
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- Trump Trade: Microsoft, Google agree to U.S. security reviews of AI models
- Novartis announces plans to add new facility in Morrisville, North Carolina
- Novartis: Buy Rating Reaffirmed as Growth Drivers and Pipeline Offset Soft Q1, $135 Price Target Maintained